Indoco Remedies Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Indoco Remedies Ltd filed with BSE on 11 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Indoco Remedies reported standalone net revenues of INR 4,291 million for Q4 FY26, up 25.8% year-on-year, driven by strong growth in international formulations across regulated and emerging markets, while domestic formulations were muted due to a weak season. Standalone EBITDA margin improved to 14.7% from 1% a year earlier. Management also disclosed an agreement to hive off the ophthalmology business in India and Africa to Sunway and discussed receivables growth, debt levels, and an ECB-related forex impact on finance costs.
Numbers mentioned
Standalone net revenue: INR 4,291 million (Q4 FY26)
p. 4
“Standalone net revenues in the company for the 4th Quarter FY '25-'26 are at INR 4,291 million compared to INR 3,411 million for the same quarter last year and INR 3,896 million for the immediately preceding quarter, that is Q3 FY '26 growing at 25.8% and 10.1% growth respectively.”
Sundeep Bambolkar, page 4 of the filed PDF · View the filing
Consolidated net revenue: INR 4,559 million (Q4 FY26)
p. 4
“Consolidated net revenues of the company for the 4th Quarter are at INR 4,559 million compared to INR 3,839 million for the same quarter last year and INR 4,343 million for the immediately preceding quarter with 18.8% and 5% growth respectively.”
Sundeep Bambolkar, page 4 of the filed PDF · View the filing
Standalone EBITDA margin: 14.7% (Q4 FY26)
p. 4
“Standalone EBITDA to net sales for the quarter is 14.7% at INR 630 million compared to 1% at INR 35 million.”
Sundeep Bambolkar, page 4 of the filed PDF · View the filing
Consolidated EBITDA margin: 10.9% (Q4 FY26)
p. 4
“Consolidated EBITDA to net sales for the quarter is 10.9% at INR 497 million compared to minus 0.2% at negative 8 million last year.”
Sundeep Bambolkar, page 4 of the filed PDF · View the filing
International formulation business revenue growth: 94.6%, INR 2,147 million (Q4 FY26)
p. 5
“Revenues from international formulation business grew by 94.6% at INR 2,147 million compared to INR 1,104 million.”
Sundeep Bambolkar, page 5 of the filed PDF · View the filing
US business revenue growth: 77.5%, INR 546 million (Q4 FY26)
p. 5
“Revenues from US business for the quarter grew by 77.5% at INR 546 million as against INR 308 million.”
Sundeep Bambolkar, page 5 of the filed PDF · View the filing
Emerging markets revenue growth: 134%, INR 746 million (Q4 FY26)
p. 5
“Revenues from emerging markets for the quarter grew by 134% at INR 746 million as against INR 318 million.”
Sundeep Bambolkar, page 5 of the filed PDF · View the filing
API business revenue: de-grew 23%, INR 315 million (Q4 FY26)
p. 5
“Revenues from API business for the quarter de-grew by 23% at INR 315 million as against INR 409 million.”
Sundeep Bambolkar, page 5 of the filed PDF · View the filing
Total consolidated debt: INR 960 crore odd, long term INR 620 crore, short term INR 344 crore (as of March 2026)
p. 6
“We are at total consolidation level, we are at 960 odd number. Long term, INR 620 crore and short term of INR 344 crore.”
Pramod Ghorpade, page 6 of the filed PDF · View the filing
Exchange loss on ECB loan impact on finance cost: INR 24 crore (Q4 FY26)
p. 9
“INR 24 crore impact.”
Pramod Ghorpade, page 9 of the filed PDF · View the filing
OTC (Warren) revenue: INR 27.4 crores (Q4 FY26)
p. 17
“For the year it is 120, I think this quarter it is INR 27.4 crores.”
Aditi Panandikar, page 17 of the filed PDF · View the filing
New product launch contribution in India: INR 20 crore (FY26)
p. 15
“In the financial year INR 20 crore and we are getting a sizable amount in new launches and they are doing very well.”
Aditi Panandikar, page 15 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Debt repayment — INR 140 crore per year · FY27, FY28, FY29
stated firmly by Pramod Ghorpade
p. 14
“So, Mr. Madhav so, next financial year which is '26-'27 we have a commitment to repay 140. Another 140 in a year after that and almost similar amount after in '28-'29 So, about INR 140 crore every year for next 3 years.”
Pramod Ghorpade, page 14 of the filed PDF · View the filing
Capex — no major capex · next 2 years
stated firmly by Pramod Ghorpade
p. 14
“No, we don't plan any major CAPEX now in next 2 years.”
Pramod Ghorpade, page 14 of the filed PDF · View the filing
Debt reduction beyond scheduled repayment — more than INR 140 crore per year
stated as an aspiration by Pramod Ghorpade
p. 14
“Our target will be to repay or to prepay a little more than this.”
Pramod Ghorpade, page 14 of the filed PDF · View the filing
Warren Remedies API business turnaround — reg market approval enabling sales · about one more year
stated conditionally by Aditi Panandikar
p. 16
“it will take us one more year to get reg market approval. We are trying to hasten it by varying site of a product from Patalganga to audit. Hopefully that should bring USFDA faster, but I cannot promise that.”
Aditi Panandikar, page 16 of the filed PDF · View the filing
India business growth — in line with IPM
stated firmly by Aditi Panandikar
p. 16
“No, in line with IPM.”
Aditi Panandikar, page 16 of the filed PDF · View the filing
Europe base contract manufacturing margins — better margins from completed MMP scale-ups · coming year
stated as an aspiration by Aditi Panandikar
p. 15
“the Europe business of base contract manufacturing will continue to grow but more than top line growth that business is likely to give us better margins in the coming year because it could be manufactured in plants which have completed all its MMP scale ups and all those things.”
Aditi Panandikar, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed the receivables growth to long credit periods in the emerging markets international business, said borrowings were broadly flat versus last year, and expressed confidence in reducing debt as performance improves.
Answered by Pramod Ghorpade
Asked by Sajal Kapoor: Why did receivables grow much faster than revenue, and what is driving stretched debt and MSME payables?
p. 6
“So, that is the primary reason of receivables, which are number of days of receivables, which are going up.”
Pramod Ghorpade, page 6 of the filed PDF · View the filing
Management explained the consolidated negative net worth figure includes both FPP and Warren, and that FPP's margins depend on whether it sells Indoco-supplied products or purchases and resells third-party finished goods.
Answered by Pramod Ghorpade
Asked by Kenil Mehta: Why did FPP's negative net worth jump from INR 34 crores to INR 82 crores in a quarter?
p. 10
“Now Kenil, you are looking at consolidated number which includes not only FPP but Warren also, another legal entity. There also we have negative number.”
Pramod Ghorpade, page 10 of the filed PDF · View the filing
Management said second manufacturing sites have been added for key sterile products which has helped supply, and that the plant issue mainly affects the timing of future approvals rather than current sales.
Answered by Aditi Panandikar
Asked by Nirmam: Will the growth in the US continue without FDA resolution of the sterile plant issue?
p. 8
“So, therefore, what will really impact us if the plant situation doesn't get resolved really is the future approvals which should be coming on time. But otherwise we are okay.”
Aditi Panandikar, page 8 of the filed PDF · View the filing
Management confirmed a repayment commitment of about INR 140 crore annually for the next three years with an intent to prepay more where possible.
Answered by Pramod Ghorpade
Asked by Madhav: What is the debt repayment expectation for FY27 and beyond?
p. 14
“So, about INR 140 crore every year for next 3 years. Our target will be to repay or to prepay a little more than this.”
Pramod Ghorpade, page 14 of the filed PDF · View the filing
Management said only one of the planned toothpaste lines has been installed and is efficiently run, while the API plant remains under validation and is not yet contributing sales, pressuring Warren Remedies' numbers.
Answered by Aditi Panandikar
Asked by Kenil Mehta: What is the capacity utilization at Warren Remedies' oral business and what initiatives are underway to grow sales?
p. 16
“It is the API plant as I said where we have both capital expenditure done, we also have operating expenses because we are doing validations of products there.”
Aditi Panandikar, page 16 of the filed PDF · View the filing
Risks flagged
Macroeconomic conditions affecting cost of goods and export disruption
p. 4
“The macroeconomic factors at this time are certainly not at all conducive for doing business, especially as regards the cost of goods and the likely disruption in exports.”
Aditi Panandikar, page 4 of the filed PDF · View the filing
Sterile plant situation not yet resolved, impacting future US approvals
p. 8
“So, that is an area of concern and we are trying to resolve that as soon as possible.”
Aditi Panandikar, page 8 of the filed PDF · View the filing
Delayed supplier payments due to cash flow situation
p. 6
“Yes, there has been some, where we have not paid suppliers on time given some of the cash flow situation we had.”
Aditi Panandikar, page 6 of the filed PDF · View the filing
Foreign currency ECB loan exposed to exchange rate volatility
p. 9
“So, this quarter exchange loss itself on a foreign currency loan, ECB loan is substantial. Almost half a portion of this finance cost is towards the exchange.”
Pramod Ghorpade, page 9 of the filed PDF · View the filing
Provision for doubtful debts increased due to a customer bankruptcy and hedging policy
p. 12
“One is one of the parties where we have supplied some material they have declared their bankruptcy. So, that is one. So, we have provided for that.”
Pramod Ghorpade, page 12 of the filed PDF · View the filing
Warren Remedies API plant products not yet generating sales due to pending approvals
p. 16
“But these validations are not resulting into sales right now because those products are not yet approved out of that site and that is putting pressure on the entire Warren Remedies numbers.”
Aditi Panandikar, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.